Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting

On March 5, 2024 Eli Lilly and Company (NYSE: LLY) reported that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 5-10 in San Diego (Press release, Eli Lilly, MAR 5, 2024, View Source [SID1234640802]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will include new preclinical data for a fully human monoclonal anti-Nectin-4 antibody conjugated to a novel topoisomerase I inhibitor and a highly potent and orally administered inhibitor of KRAS G12D that is selective against wild-type KRAS. In addition, preclinical data on a potent and selective BRM (SMARCA2) inhibitor for the treatment of BRG1 (SMARCA4) mutated cancers will be presented in collaboration with Foghorn Therapeutics. Investigational New Drug (INDs) applications are planned for all three programs in 2024.

Details on poster presentations are below:

Presentation Title: A next generation treatment for Nectin-4 positive cancers – Preclinical characterization of LY4052031, an anti-Nectin-4 antibody, conjugated to a novel camptothecin payload
Abstract Number: 1872
Session Date & Time: Monday, April 8, 9:00 a.m. – 12:30 p.m. PT
Session Title: Antibody-Based Technologies and New Inhibitors
Presenter: Divya Sagar

Presentation Title: LY3962673, an oral, highly potent, mutant-selective, and non-covalent KRAS G12D inhibitor demonstrates robust anti-tumor activity in KRAS G12D models
Abstract Number: 3316
Session Date & Time: Monday, April 8, 1:30 p.m. – 5:00 p.m. PT
Session Title: Novel Antitumor Agents 3
Presenter: Xueqian Gong

Presentation Title: Discovery of selective BRM (SMARCA2) ATPase inhibitors for the treatment of BRG1 (SMARCA4) mutant cancers
Abstract Number: 3230
Session Date & Time: Monday, April 8, 1:30 p.m. – 5:00 p.m. PT
Session Title: Epigenetic Targets
Presenter: Janice Lee